Sander Flaum MM+M - Medical Marketing and Media

Sander Flaum

Most recent articles by Sander Flaum

Cost of innovation making fight against superbugs near impossible
Cost of innovation making fight against superbugs near impossible
Sander Flaum
February 7, 2020
5:00 am

Sander Flaum discusses the DISARM act and how we can fight back against antibiotic resistance.

Don’t believe the bluster: Many Americans like their healthcare
Don’t believe the bluster: Many Americans like their healthcare
Sander Flaum
December 18, 2019
5:00 am

Contrary to popular belief, most Americans like their healthcare and don’t want to change it.

Corporations are people – and they are beginning to act like it
Corporations are people – and they are beginning to act like it
Sander Flaum
August 2, 2019
10:17 am

CVS is pushing into primary care. If successful, might this prove that corporations can fulfill the Democratic dream of socialized health?

Amgen’s innovative osteoporosis drug is something we can all get behind
Amgen’s innovative osteoporosis drug is something we can all get behind
Sander Flaum
May 17, 2019
5:00 am

Sander Flaum is principal of Flaum Navigators.

Pharma can’t win with critics, even when it makes breakthroughs
Pharma can’t win with critics, even when it makes breakthroughs
Sander Flaum
May 3, 2019
5:00 am

Even when pharma produces breakthroughs, critics still find something or other to nitpick.

Continued research depends on fair prices for treatments
Continued research depends on fair prices for treatments
Sander Flaum
April 5, 2019
5:00 am

Sander Flaum explains why continued research depends on fair prices for treatments.

Why health insurers want to cast pharma as a villain
Why health insurers want to cast pharma as a villain
Sander Flaum
March 8, 2019
5:00 am

Sander Flaum takes a look at why health insurers want to cast pharma as the villain.

Focus on drugs’ cost may prevent their discovery
Focus on drugs’ cost may prevent their discovery
Sander Flaum
December 5, 2018
7:00 am

Breakthrough drugs will eventually be more affordable, but a misplaced focus on their cost may prevent them from being discovered at all.

Pharma must consider new approach to opioid crisis
Pharma must consider new approach to opioid crisis
Sander Flaum
November 7, 2018
7:00 am

As more and more people die from opioid overdoses, it’s time for pharma to own up to its collective responsibility and come up with a solution.

Should big pharma begin thinking a little smaller?
Should big pharma begin thinking a little smaller?
Sander Flaum
October 4, 2018
6:00 am

Big pharma should extend its vision beyond the blockbusters to make room for orphan drugs.

  • Culture drives the company

    Get to know each of these companies by learning about their culture, work/life balance, D&I initiatives and more.

  • From Our Partners